Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Non-Small-Cell Lung 3Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Prostate Adenocarcinoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Liver Diseases 1Liposarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Breast Neoplasms 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × Adjuvants, Pharmaceutic × Clear all
NCT06218511 2025-12-22

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

National Cancer Institute, Naples

Phase 1 Active not recruiting
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04727307 2025-09-30

AB-LATE02

University Hospital, Montpellier

Phase 2 Recruiting
202 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡